• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Showcases Next‑Generation Automated Solutions at SLAS2026

    2/4/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Connected with confidence to accelerate scientific discovery

    Agilent Technologies Inc. (NYSE:A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency, and superior data quality.

    Agilent's automation philosophy emphasizes open connectivity and strong collaboration with leading robotics and workflow‑automation developers. At SLAS2026, visitors will see examples of Agilent instrumentation integrated into multi‑vendor automated environments—including systems developed with ABB Robotics, HighRes Biosolutions, Biosero, and Unite Labs.

    The showcase includes a preview of the upcoming addition to the Cytation imaging family. Designed with enhanced imaging optics and faster, more efficient data acquisition, the new platform advances high‑content imaging capabilities for research and screening applications.

    Agilent will also debut the ProteoAnalyzer Software Security Module, a compliance‑enabling software enhancement that helps pharmaceutical and biopharmaceutical manufacturing labs meet stringent global regulatory requirements, including 21 CFR Part 11 and Annex 11. The module adds secure user authentication, detailed audit trails, permission controls, and electronic signatures to strengthen data integrity and audit readiness across regulated workflows.

    Agilent will feature new AI‑driven lab optimization tools integrated into its CrossLab Connect platform, enabled by Sigsense intelligent monitoring technology. This enhancement provides real‑time performance insights, asset‑utilization analytics, and predictive alerts to help laboratories reduce downtime and enhance operational productivity. Attendees will also see continued progress across automation‑ready workflows, including new Bravo liquid‑handling protocols such as GLP‑1 agonist sample preparation.

    "SLAS is the ideal forum to demonstrate how Agilent's automation solutions enable researchers to achieve breakthroughs faster and with greater confidence," said Shweta Shukradas, Associate Vice President and Business Lead, Automated Productivity Solutions. "Our investments in imaging, compliance‑ready software, robotics partnerships, and AI‑enabled optimization reflect our commitment to helping customers build the automated lab of the future."

    Conference attendees can visit Agilent booth #1808 to explore live demonstrations, meet technical experts, and learn how Agilent solutions support end‑to‑end automation across cell analysis, genomics, biomolecule characterization, and analytical workflows. Agilent will also participate in multiple presentations and tutorials throughout the conference.

    Agilent will host two Exhibitor Tutorial Sessions at SLAS2026. "Towards the Digital and Automated Lab," presented by Anneke Muehlebach, Product Marketing Director in Agilent's Software Informatics Division, will take place on Monday, February 9, from 2:00 PM ET to 3:00 PM ET in room 104C exploring how guided workflows, advanced tracking, and collaborative robotics are accelerating the transition toward autonomous laboratory environments.

    "Utilizing High‑Throughput AssayMAP Bravo for Drug Stability, PK, and Immunogenicity Assessment," led by Nadia Sultana, Senior Scientist at AbbVie, will be held on Tuesday, February 10, from 2:00 PM ET to 3:00 PM ET in room 104C detailing automated sample‑preparation workflows that enhance accuracy and throughput across drug‑development applications.

    A Solutions Spotlight Presentation "The Next Generation of Hybrid Analysis: Expanding Possibilities in Automated Cell Imaging and Detection" will be held Tuesday, February 10, beginning at 3:30 PM ET in the SLAS Solutions Spotlight Theater highlighting the Agilent BioTek Cytation platform presented by Bikram Chakraborty, Director of Product Management, Agilent Technologies-BioTek and Seahorse product lines, Agilent.

    Additionally, Agilent will participate in a roundtable discussion entitled, "From Insight to Impact: AI, Robotics and the Convergence toward the Lab of the Future" hosted by ABB Robotics on Tuesday, February 10, from 12:00 PM ET to 1:15 PM ET in Room 107A.

    Agilent's continued advancements in automation, AI, and instrument‑software integration reinforce its role as a premier partner for laboratories seeking higher throughput, improved reproducibility, and trusted answers to complex scientific questions. Agilent is a proud Gold Sponsor of the SLAS2026 International Conference & Exhibition, highlighting Agilent's commitment to advancing laboratory automation and life sciences discovery.

    About Agilent Technologies

    Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260204034151/en/

    Media Contact:

    Kate Coyle

    Agilent Technologies Inc.

    +1 302-633-7490

    [email protected]

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy
    HSBC Securities
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    12/9/2025$170.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    10/8/2025$170.00Neutral → Buy
    UBS
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

    Agilent Technologies Inc. (NYSE:A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics' CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides cus

    3/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies

    Agilent to acquire Biocare in an all-cash transaction valued at $950 millionTransaction follows significant period of growth under Excellere Partners and GHO Capital stewardship, with annual double-digit revenue and profit growth since 2021 Denver, CO and London, UK, 9 March 2026: Excellere Partners ("Excellere"), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP ("GHO"), a specialist investor in global healthcare, and Biocare Medical ("Biocare"), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has enter

    3/9/26 3:05:31 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

    Expands Agilent's pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent's top-line growth rate, margin profile and non-instrument revenue mix in Year 1 Agilent Technologies Inc. (NYSE:A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portf

    3/9/26 3:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/6/26 4:05:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    3/3/26 4:17:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/25/26 4:06:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Riemann Angelica covered exercise/tax liability with 89 shares, decreasing direct ownership by 0.33% to 26,535 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/3/26 4:09:49 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig covered exercise/tax liability with 279 shares, decreasing direct ownership by 0.42% to 66,260 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/3/26 4:08:01 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 124 shares, decreasing direct ownership by 0.87% to 14,138 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    3/3/26 4:06:15 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

    Delivers solid Q1 results, raises FY26 reported revenue outlook and increases non-GAAP EPS(3) guidance while confirming core-revenue growth(1) and margin expansion First-quarter fiscal year 2026 Revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% on a core(1) basis compared with the first quarter of 2025. GAAP net income of $305 million; earnings per share (EPS) of $1.07, a decline of 4% from the first quarter of 2025. Non-GAAP(2) net income of $386 million; non-GAAP EPS(3) of $1.36, growing 4% from the first quarter of 2025. Fiscal year 2026 and second-quarter outlook Fiscal year 2026 revenue is expected in t

    2/25/26 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials